Cargando…

Engineering of Human Corneal Endothelial Cells In Vitro

Human corneal endothelial cells are responsible for controlling corneal transparency, however they are notorious for their limited proliferative capability. Thus, damage to these cells may cause irreversible blindness. Currently, the only way to cure blindness caused by corneal endothelial dysfuncti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Qin, Zhu, Yingting, Tighe, Sean, Liu, Yongsong, Hu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535652/
https://www.ncbi.nlm.nih.gov/pubmed/31171901
http://dx.doi.org/10.7150/ijms.30759
_version_ 1783421594797867008
author Zhu, Qin
Zhu, Yingting
Tighe, Sean
Liu, Yongsong
Hu, Min
author_facet Zhu, Qin
Zhu, Yingting
Tighe, Sean
Liu, Yongsong
Hu, Min
author_sort Zhu, Qin
collection PubMed
description Human corneal endothelial cells are responsible for controlling corneal transparency, however they are notorious for their limited proliferative capability. Thus, damage to these cells may cause irreversible blindness. Currently, the only way to cure blindness caused by corneal endothelial dysfunction is via corneal transplantation of a cadaver donor cornea with healthy corneal endothelium. Due to severe shortage of donor corneas worldwide, it has become paramount to develop human corneal endothelial grafts in vitro that can subsequently be transplanted in humans. Recently, we have reported effective expansion of human corneal endothelial cells by reprogramming the cells into progenitor status through use of p120-Kaiso siRNA knockdown. This new reprogramming approach circumvents the need of using induced pluripotent stem cells or embryonic stem cells. Successful promotion of this technology will encourage scientists to re-think how "contact inhibition" can safely be perturbed to our benefit, i.e., effective engineering of an in vivo-like tissue while successful maintaining the normal phenotype. In this review, we present current advances in reprogramming corneal endothelial cells in vitro, detail the methods to successful engineer human corneal endothelial grafts, and discuss their future clinical applications to cure corneal blindness.
format Online
Article
Text
id pubmed-6535652
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-65356522019-06-06 Engineering of Human Corneal Endothelial Cells In Vitro Zhu, Qin Zhu, Yingting Tighe, Sean Liu, Yongsong Hu, Min Int J Med Sci Review Human corneal endothelial cells are responsible for controlling corneal transparency, however they are notorious for their limited proliferative capability. Thus, damage to these cells may cause irreversible blindness. Currently, the only way to cure blindness caused by corneal endothelial dysfunction is via corneal transplantation of a cadaver donor cornea with healthy corneal endothelium. Due to severe shortage of donor corneas worldwide, it has become paramount to develop human corneal endothelial grafts in vitro that can subsequently be transplanted in humans. Recently, we have reported effective expansion of human corneal endothelial cells by reprogramming the cells into progenitor status through use of p120-Kaiso siRNA knockdown. This new reprogramming approach circumvents the need of using induced pluripotent stem cells or embryonic stem cells. Successful promotion of this technology will encourage scientists to re-think how "contact inhibition" can safely be perturbed to our benefit, i.e., effective engineering of an in vivo-like tissue while successful maintaining the normal phenotype. In this review, we present current advances in reprogramming corneal endothelial cells in vitro, detail the methods to successful engineer human corneal endothelial grafts, and discuss their future clinical applications to cure corneal blindness. Ivyspring International Publisher 2019-03-10 /pmc/articles/PMC6535652/ /pubmed/31171901 http://dx.doi.org/10.7150/ijms.30759 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Zhu, Qin
Zhu, Yingting
Tighe, Sean
Liu, Yongsong
Hu, Min
Engineering of Human Corneal Endothelial Cells In Vitro
title Engineering of Human Corneal Endothelial Cells In Vitro
title_full Engineering of Human Corneal Endothelial Cells In Vitro
title_fullStr Engineering of Human Corneal Endothelial Cells In Vitro
title_full_unstemmed Engineering of Human Corneal Endothelial Cells In Vitro
title_short Engineering of Human Corneal Endothelial Cells In Vitro
title_sort engineering of human corneal endothelial cells in vitro
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535652/
https://www.ncbi.nlm.nih.gov/pubmed/31171901
http://dx.doi.org/10.7150/ijms.30759
work_keys_str_mv AT zhuqin engineeringofhumancornealendothelialcellsinvitro
AT zhuyingting engineeringofhumancornealendothelialcellsinvitro
AT tighesean engineeringofhumancornealendothelialcellsinvitro
AT liuyongsong engineeringofhumancornealendothelialcellsinvitro
AT humin engineeringofhumancornealendothelialcellsinvitro